In December 2019, the first case of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) was described and by March 2020, the World Health Organization had declared the disease (Coronavirus disease 2019, COVID-19) a pandemic. Whilst respiratory symptoms are the fundamental feature of the disease, evidence indicates that the disease is associated with coagulation dysfunction which predisposes patients to an increased risk of both venous and arterial thromboembolism (TE) and potentially increased mortality risk as a consequence. Biomarkers associated with TE (D-dimers) are often raised in people with COVID but without clear evidence of TE. It is important to understand who is at most risk of TE, to manage disease effectively. This dataset (in OMOP) describes patients with and without COVID who were admitted to UHB including all those with and without TE.